| Operating Income (202 206 210 211) |
| 1. Income from sales of merchandise goods (203 through 205) |
| a) to related legal entities |
| b) on domestic market |
| c) on foreign market |
| 2. Income from sale of products (207 through 209) |
| a) to related legal entities |
| b) on domestic market |
| c) on foreign market |
| 3. Income from activation or consumption of goods, products and services |
| 4. Other operating income |
| Operating Expenses (213 214 215 219 220 221 222 223 224) |
| 1. Merchandise goods sold at cost |
| 2. Materials expenses |
| 3. Wages, salaries and other employee benefits expenses (216 through 218) |
| a) Gross wages and gross salaries |
| b) Other employee expenses |
| c) Other individual expenses |
| 4. Services expense |
| 5. Depreciation |
| 6. Provisions expenses |
| 7. Immaterial expense |
| Increase in value of products in stock |
| Decrease in value of products in stock |
| Operating income (201-212) |
| Operating Loss (212-201) |
| Finance Income (228 through 233) |
| 1. Finance income from related legal entities |
| 2. Interest income |
| 3. Foreign exchange gains |
| 4. Incomes from currency clause |
| 5. Income from joint venture investments |
| 6. Other finance income |
| Finance Expenses (235 through 239) |
| 1. Finance expenses from relations with related legal entities |
| 2. Interests expense |
| 3. Foreign exchange losses |
| 4. Currency clause expenses |
| 5. Other finance expense |
| Finance income (227-234) |
| Finance loss (234-227) |
| Operating income(225-226 240-241) > 0 |
| Operating loss (225-226 240-241) < 0 |
| Other income (245 through 253) |
| 1. Income from sale of fixed assets |
| 2. Income from sale of investment property |
| 3. Income from sale of biological assets |
| 4. Income from sale of stakes in capital and long-term securities |
| 5. Income from sale of materials |
| 6. Surpluses |
| 7. Collected written-off receivables |
| 8. Incomes from contractually agreed risk protection |
| 9. Written-off liabilities, termination of provisions and other incomes |
| Other expenses (255 through 263) |
| 1. Losses arising from sale and write-off of fixed assets |
| 2. Losses arising from sale and write off of investment property |
| 3. Losses arising from sale and write off of biological assets |
| 4. Losses from sale of stakes in capital and long-term securities |
| 5. Losses from sale of materials |
| 6. Deficits |
| 7. Losses from risk protection |
| 8. Losses from revaluation and write-offs |
| 9. Losses from products in stocks and other losses |
| Gain from other incomes and expenses (244-254) |
| Loss from other incomes and expenses (254-244) |
| Income from revaluation of value (267 through 275) |
| 1. Income from revaluation of intangible assets |
| 2. Income from revaluation of real-estates, plant and equipment |
| 3. Income from revaluation of investment property which is subject to depreciation |
| 4. Income from revaluation of biological assets which are subject to depreciation |
| 5. Income from revaluation of long-term financial placements and financial assets available for sale |
| 6. Income from revaluation of products in stock |
| 7. Income from revaluation of short-term financial placements |
| 8. Income from revaluation of capital value |
| 9. Income from revaluation of other property value |
| Losses from revaluation of proprerty value (277 through 284) |
| 1. Impairment of intangible assets |
| 2. Impairment of real-estates, plant and equipment |
| 3. Impairment of investment property which is subject to depreciation |
| 4. Impairment of biological assets which are subject to depreciation |
| 5. Impairment of long-term financial placements and financial assets available for sale |
| 6. Impairment of products in stock |
| 7. Impairment of short-term financial placements |
| 8. Impairment of other property value |
| Increase of the value of specific fixed assets (286 through 288) |
| Increase of the value of investment properties that are not subject to depreciation |
| Increase of the value of biological assets that are not subject to depreciation |
| Increase of the value of other property values that are not subject to depreciation |
| Decrease of the value of specific fixed assets (290 through 292) |
| Decrease of the value of investment properties that are not subject to depreciation |
| Decrease of the value of biological assets that are not subject to depreciation |
| Decrease of the value of other property values that are not subject to depreciation |
| Revaluation gain (266-276 285-289) > 0 |
| Revaluation loss (266-276 285-289) < 0 |
| Incomes from changes in accounting policies and corrections from previous year |
| Losses from changes in accounting policies and corrections from previous year |
| Income before taxes (242-243 264-265 293-294 295-296) > 0 |
| Loss before taxes (242-243 264-265 293-294 295-296) < 0 |
| Tax expenses of reporting period |
| Deferred tax expenses of reporting period |
| Deferred tax incomes of reporting period |
| Net income (297-298-299-300 301) > 0 |
| Net loss (297-298-299-300 301) < 0 |
| Income from sale and revaluation of assets available for sale and discontinued operations assets |
| Loss from sale and revaluation of assets available for sale and discontinued operations assets |
| Income from discontinued operations (304-305) |
| Loss from discontinued operations (305-304) |
| Tax on discontinued operations |
| Net income from discontinued operations (306-307-308) > 0 |
| Net loss from discontinued operations (306-307-308) < 0 |
| Net income of the period (302-303 309-310) > 0 |
| Net loss of the period (302-303 309-310) < 0 |
| Interim dividends and other net income distributions during reporting period |
| Gains determined directly in capital (equity) (315 through 320) |
| 1. Gains from realization of revaluation reserves for fixed assets |
| 2. Gains from changes in fair value of securities available for sale |
| 3. Gains arising from translation of financial statements in foreign operations |
| 4. Actuarial gains from defined-benefit plans |
| 5. Effective share of gains arising from cash-flow risk protection |
| 6. Other unrealized gains and gains determined directly in capital (equity) |
| Loss determined directly in capital (equity) (322 through 326) |
| 1. Losses from changes in fair value of securities available for sale |
| 2. Losses arising from translation of financial statements in foreign operations |
| 3. Actuarial losses from defined-benefit plans |
| 4. Effective share of losses arising from cash-flow risk protection |
| 5. Other unrealized losses and losses determined directly in capital (equity) |
| Other total income before tax (314-321) |
| Other total loss before tax (321-314) |
| Accrued Deferred tax on other total income |
| Other total net income (327-328-329) > 0 |
| Other total net loss (327-328-329) < 0 |
| Total net income of the period (327-328-329) > 0 |
| Total net loss of the period (311-312 330-331) < 0 |
| Net income/loss of the period which belongs to owners (311 or 312) |
| a) Majority owners |
| b) Minority owners |
| Total Net income/loss of the period which belongs to owners (332 or 333) |
| a) Majority owners |
| b) Minority owners |
| Earnings per share |
| a) Basic |
| b) Diluted |
| - based on the working hour |
| - according to month ending balance |